Firebrick Pharma Limited (ASX:FRE)

Firebrick Pharma Balance Sheet

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	1.44	0.98	0.82	2.35	7.14	1.15
Short-Term Investments	-	-	-	-	-	0.01
Cash & Short-Term Investments	1.44	0.98	0.82	2.35	7.14	1.16
Cash Growth	57.49%	19.23%	-64.97%	-67.04%	514.47%	1153.94%
Accounts Receivable	0.01	0.01	0	-	-	-
Other Receivables	0.03	0.25	0.95	0.14	1.08	0.5
Receivables	0.04	0.26	0.95	0.14	1.08	0.5
Inventory	0.59	0.19	0.24	-	-	-
Prepaid Expenses	0.09	-	-	-	-	0
Other Current Assets	0.01	0.05	0.08	0.1	0.1	-
Total Current Assets	2.16	1.48	2.09	2.59	8.33	1.67
Property, Plant & Equipment	0.11	0.09	0.03	0.03	0.04	0.02
Other Long-Term Assets	0.01	0.25	0.29	0.36	0.36	0.08
Total Assets	2.28	1.83	2.41	2.98	8.73	1.76
Accounts Payable	0.16	0.11	0.07	0.2	0.04	0.03
Accrued Expenses	0.02	0.12	0.1	0.14	0.34	0.1
Other Current Liabilities	0.17	0.04	0.12	0.17	0.08	0.08
Total Current Liabilities	0.34	0.27	0.29	0.51	0.45	0.21
Total Liabilities	0.34	0.27	0.29	0.51	0.45	0.21
Common Stock	21.45	19.77	17.88	17.07	16	5.77
Retained Earnings	-19.87	-18.79	-16.51	-15.58	-8.81	-5.03
Comprehensive Income & Other	0.36	0.57	0.74	0.99	1.08	0.81
Shareholders' Equity	1.94	1.56	2.12	2.48	8.28	1.55
Total Liabilities & Equity	2.28	1.83	2.41	2.98	8.73	1.76
Net Cash (Debt)	1.44	0.98	0.82	2.35	7.14	1.16
Net Cash Growth	57.49%	19.23%	-64.97%	-67.04%	514.47%	2935.77%
Net Cash Per Share	0.01	0.00	0.00	0.01	0.06	0.01
Filing Date Shares Outstanding	251.57	227.32	195.31	176.25	169.2	37.21
Total Common Shares Outstanding	251.57	224.58	195.31	176.25	168.84	37.21
Working Capital	1.82	1.21	1.8	2.08	7.88	1.45
Book Value Per Share	0.01	0.01	0.01	0.01	0.05	0.04
Tangible Book Value	1.94	1.56	2.12	2.48	8.28	1.55
Tangible Book Value Per Share	0.01	0.01	0.01	0.01	0.05	0.04
Machinery	-	-	-	-	-	0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.